20May 2023
Trends in Price, Spending, and Utilization of Omalizumab Among Medicare Beneficiaries

Trends in Price, Spending, and Utilization of Omalizumab Among Medicare Beneficiaries

From January 2005 to 2023, the average selling price of omalizumab, a medication used for asthma and chronic idiopathic urticaria, increased by almost 60%. Medicare Part B and D spending on omalizumab between 2016 and 2021 amounted to over $3.7 billion. During the same period, the utilization of omalizumab under Medicare Part B and D increased by approximately 30%. These findings highlight the significant cost and usage trends associated with omalizumab over the past decade, indicating its importance and impact on healthcare expenditures.

  • #ent

Like

Save

Share